scholarly journals Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma

2021 ◽  
Author(s):  
Koji Nakajima ◽  
Ayumi Korekawa ◽  
Daiki Rokunohe ◽  
Hajime Nakano ◽  
Daisuke Sawamura
Keyword(s):  
Metastatic Melanoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Term Administration

scholarly journals Recurrent checkpoint inhibitor‐induced warm agglutinin autoimmune hemolytic anemia in a patient with metastatic melanoma

2020 ◽  
Vol 95 (7) ◽  
Author(s):  
Steven R. Hwang ◽  
Timothy O'Dowd ◽  
Svetomir N. Markovic ◽  
Alexandra P. Wolanskyj‐Spinner
Keyword(s):  
Metastatic Melanoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Checkpoint Inhibitor

scholarly journals Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia

Hematology ◽  
2016 ◽  
Vol 21 (6) ◽  
pp. 368-374 ◽  
Author(s):  
Ekarat Rattarittamrong ◽  
Prot Eiamprapai ◽  
Adisak Tantiworawit ◽  
Thanawat Rattanathammethee ◽  
Sasinee Hantrakool ◽  
...  
Keyword(s):  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Clinical Characteristics ◽  
Long Term Outcomes

scholarly journals B-lymphocyte reconstitution after repeated rituximab treatment in a child with steroid-dependent autoimmune hemolytic anemia

2011 ◽  
Vol 3 (4) ◽  
pp. 28 ◽  
Author(s):  
Annelieke A.A. Van der Linde ◽  
Ellen J.H. Schatorjé ◽  
Annemieke M. Van der Weij ◽  
Eugenie F.A. Gemen ◽  
Esther De Vries
Keyword(s):  
B Lymphocytes ◽  
Hemolytic Anemia ◽  
Antibody Production ◽  
Specific Antibody ◽  
Autoimmune Hemolytic Anemia ◽  
B Lymphocyte ◽  
Lymphocyte Subpopulations ◽  
Steroid Dependent ◽  
Specific Antibody Production

We report the detailed long-term reconstitution of B-lymphocyte subpopulations, immunoglobulins, and specific antibody production after two courses of rituximab in a young, previously healthy girl with steroid-dependent autoimmune hemolytic anemia. B-lymphocyte subpopulations were surprisingly normal directly after reconstitution. However, there was a slower reconstitution after the second rituximab course, especially of non-switched and switched memory B-lymphocytes, and a temporary decline in IgM below age-matched reference values.

scholarly journals Autoimmune Hemolytic Anemia and Immune Thrombocytopenia: A Unique Presentation of Kawasaki Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Chloe Kupelian ◽  
Bindu Sathi ◽  
Deepika Singh
Keyword(s):  
Coronary Artery ◽  
Kawasaki Disease ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Immune Thrombocytopenia ◽  
Cervical Lymphadenopathy ◽  
Clinical Findings ◽  
Normocytic Anemia ◽  
Coronary Aneurysms

Kawasaki disease is an acute multisystem vasculitis characterized by involvement of medium-sized vessels that mostly affects children under the age of 5 years. The presentation is typically preceded by five or more days of fever with additional clinical findings including rash, peripheral edema, mucositis, conjunctival changes, and unilateral cervical lymphadenopathy. The most feared complication of Kawasaki disease is development of coronary artery aneurysms. Common laboratory abnormalities include normocytic anemia, thrombocytosis, leukocytosis, and elevated inflammatory markers. Immune-mediated cytopenias such as autoimmune hemolytic anemia and thrombocytopenia are rarely seen at presentation in Kawasaki disease. We describe a unique case of a child presenting with autoimmune hemolytic anemia, who sequentially developed immune thrombocytopenia concerning for Evans’ syndrome and eventually diagnosed with Kawasaki Disease with coronary artery dilatation. Characteristic clinical findings including extremity edema, cracked lips, and rash developed later in the course. Our patient was treated with IVIG and steroids with significant clinical improvement and complete resolution of cytopenias and coronary aneurysms on long term follow up. Timely administration of IVIG prevents and minimizes the risk of long term cardiac consequences. Hence a high index of suspicion should be maintained for this relatively common pediatric illness, even in absence of more commonly seen laboratory findings.

scholarly journals Autoimmune Hemolytic Anemia in the Pediatric Setting

2021 ◽  
Vol 10 (2) ◽  
pp. 216
Author(s):  
Aikaterini Voulgaridou ◽  
Theodosia A. Kalfa
Keyword(s):  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Positive Outcome ◽  
Cold Temperatures ◽  
Negative Results ◽  
Splenic Macrophages ◽  
Immune Mediated ◽  
Post Infectious ◽  
Paroxysmal Cold Hemoglobinuria

Autoimmune hemolytic anemia (AIHA) is a rare disease in children, presenting with variable severity. Most commonly, warm-reactive IgG antibodies bind erythrocytes at 37 °C and induce opsonization and phagocytosis mainly by the splenic macrophages, causing warm AIHA (w-AIHA). Post-infectious cold-reactive antibodies can also lead to hemolysis following the patient’s exposure to cold temperatures, causing cold agglutinin syndrome (CAS) due to IgM autoantibodies, or paroxysmal cold hemoglobinuria (PCH) due to atypical IgG autoantibodies which bind their target RBC antigen and fix complement at 4 °C. Cold-reactive antibodies mainly induce intravascular hemolysis after complement activation. Direct antiglobulin test (DAT) is the gold standard for AIHA diagnosis; however, DAT negative results are seen in up to 11% of warm AIHA, highlighting the need to pursue further evaluation in cases with a phenotype compatible with immune-mediated hemolytic anemia despite negative DAT. Prompt supportive care, initiation of treatment with steroids for w-AIHA, and transfusion if necessary for symptomatic or fast-evolving anemia is crucial for a positive outcome. w-AIHA in children is often secondary to underlying immune dysregulation syndromes and thus, screening for such disorders is recommended at presentation, before initiating treatment with immunosuppressants, to determine prognosis and optimize long-term management potentially with novel targeted medications.

scholarly journals Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia

2020 ◽  
Vol 9 (12) ◽  
pp. 4034
Author(s):  
Irina Murakhovskaya
Keyword(s):  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Blood Cells ◽  
Rare Condition ◽  
Cold Agglutinin ◽  
Toxicity Profile ◽  
Cold Agglutinin Disease ◽  
First Line ◽  
Hematologic Disorder

Autoimmune hemolytic anemia is a rare condition characterized by destruction of red blood cells with and without involvement of complement. It is associated with significant morbidity and mortality. In warm autoimmune hemolytic anemia, less than 50% of patients remain in long-term remission following initial steroid therapy and subsequent therapies are required. Cold agglutinin disease is a clonal hematologic disorder that requires therapy in the majority of patients and responds poorly to steroids and alkylators. Rituximab has a favorable toxicity profile and has demonstrated efficacy in autoimmune hemolytic anemia in first-line as well as relapsed settings. Rituximab is the preferred therapy for steroid refractory warm autoimmune hemolytic anemia (wAIHA) and as part of the first- and second-line treatment of cold agglutinin disease. This article reviews the mechanism of action of rituximab and the current literature on its role in the management of primary and secondary warm autoimmune hemolytic anemia and cold agglutinin disease.

scholarly journals Rituximab use in Warm and Cold Autoimmune Hemolytic Anemia

2020 ◽  
Author(s):  
Irina Murakhovskaya
Keyword(s):  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Blood Cells ◽  
Rare Condition ◽  
Cold Agglutinin ◽  
Toxicity Profile ◽  
Cold Agglutinin Disease ◽  
First Line ◽  
Hematologic Disorder

Autoimmune hemolytic anemia is a rare condition characterized by destruction of red blood cells with and without involvement of complement. It is associated with significant morbidity and mortality. In warm autoimmune hemolytic anemia less than 50% of patients remain in a long-term remission following initial steroid therapy and subsequent therapies are required. Cold agglutinin disease is a clonal hematologic disorder which requires therapy in majority of patients and responds poorly to steroids and alkylators. Rituximab has a favorable toxicity profile and has demonstrated efficacy in autoimmune hemolytic anemia in first line as well as relapsed setting. Rituximab is the preferred therapy for steroid refractory wAIHA and as part of the first- and second-line treatment of cold agglutinin disease. This article reviews the mechanism of action of the rituximab and current literature its role in management of primary and secondary warm autoimmune hemolytic anemia and cold agglutinin disease.

Giant Cell Hepatitis with Autoimmune Hemolytic Anemia in Early Childhood: Long-Term Outcome in 16 Children

2011 ◽  
Vol 159 (1) ◽  
pp. 127-132.e1 ◽  
Author(s):  
Giuseppe Maggiore ◽  
Marco Sciveres ◽  
Monique Fabre ◽  
Laura Gori ◽  
Lucia Pacifico ◽  
...  
Keyword(s):  
Early Childhood ◽  
Giant Cell ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Giant Cell Hepatitis
Sign in / Sign up

Export Citation Format

Share Document